Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. - Test2 - elhamkhani - TriplyDB

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

http://www.wikidata.org/entity/Q37318124

about

Fundamentals of cancer metabolism Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics Melanoma: oncogenic drivers and the immune system Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy MYC, Metabolism, and Cancer Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity Pathways and therapeutic targets in melanoma Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers Targeting mitochondria metabolism for cancer therapy Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Metabolic rewiring in melanoma ROS homeostasis and metabolism: a dangerous liason in cancer cells Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach.Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.Phenformin Induces Cell Cycle Change, Apoptosis, and Mesenchymal-Epithelial Transition and Regulates the AMPK/mTOR/p70s6k and MAPK/ERK Pathways in Breast Cancer Cells Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation.Molecular Pathways: Is AMPK a Friend or a Foe in Cancer?Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth.Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.Metabolic vulnerability in melanoma: a ME2 (me too) story Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression.Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3.AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC.Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors.LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism.Is it time to test biguanide metformin in the treatment of melanoma?Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma.AMPK--sensing energy while talking to other signaling pathways.Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells.Melanoma stem cells.Emerging targets for combination therapy in melanomas.

P2860

Q26744062-FECF3570-5DD5-4529-9276-DE4A222C707E Q26771751-4925DBA7-D30A-4366-9D3B-0EC0FEE22BA9 Q26775598-349FDB6F-5A03-41BC-B05B-61B988532520 Q26783032-763EF754-9B45-4F0C-8933-DCC74554B61D Q26783555-8ECD81E0-5D4F-4444-99C1-C81CDB27594E Q26795735-AD436049-28D7-41AF-8275-5A5A643E4A21 Q26796292-0C64C224-CD56-48E3-9B1C-20B9FD344ACA Q26865736-7C093B75-3463-4955-B084-E33A3CA51D4C Q27022240-753A8483-9523-4619-AFDE-9132D3C523AD Q27027219-3DA3FCF8-DF4A-40E1-9262-837EDC741607 Q27853104-FFAE42F0-65D4-4B65-B00E-06CAAC011919 Q28069081-AB828B3B-FD55-481C-A7C7-5BF85EB22AD5 Q28075971-9F8F05CF-AC26-485A-A0C2-8D8DCDE093C0 Q28551227-7CAAA261-E5D9-4576-BFDF-89F903EF0010 Q33560698-7AFCD5CE-A067-470E-955A-C50D92517999 Q33639714-5FF5A6CA-25CE-4897-981E-1070BF0AD430 Q34533709-B84A6007-7858-4328-AFC2-D2558B0A2978 Q35550181-3AD07F64-EE7C-43F2-B018-F796603D1EC8 Q35675277-04C4BF46-DA10-4D12-96E6-061A89F46999 Q35957526-93682FF4-5940-455F-B16E-D860FCF48715 Q36016760-53EAF2C7-F0AD-48D0-830A-41138B047E15 Q36023587-4887B292-6674-48B2-B7D1-F0994B0E2661 Q36191986-DD1EA041-B74A-474A-9E3E-EE08C4D448FB Q36398758-D764201F-258D-4FE2-A87F-C028719B4669 Q36398834-DD60835B-91A5-46F1-9523-D4807C66F30E Q36476849-B4A3859B-CA02-48D4-9AE0-A42E566D9114 Q36545458-58817008-C4FB-41E7-A8D1-F0176A6FE876 Q36545721-3A27930E-A33D-465F-8202-0C99E2A4432D Q36682137-D987199D-1D69-4EFA-B372-E57B02B1B2CA Q36976172-81C8EE7D-CF68-4EBC-ABE0-0FC79C9C78D4 Q37151297-115103E4-0849-4DA1-A35B-8A8170C2D891 Q37239090-8911DA4B-C690-4EFC-99DA-852CAE5ED641 Q37457568-7A9152CB-C7F0-475B-878B-D66DEE8796FF Q37660888-7BA1C1F6-1BFF-4E9D-81C1-9CB3242552E6 Q38215034-CE199726-1206-4777-AFBC-73F3AD06E258 Q38238524-7859E0E0-5F54-455A-8808-6CBED19DEB1B Q38275424-40F5BAF2-4405-4F6C-BF51-EC6CE897D209 Q38322466-76B188B4-381C-48C6-BF31-D657568841AF Q38335943-CDCF8799-B2D6-4B60-8626-438DCD2F295F Q38602788-09FE8639-C1CA-4625-9002-067AE06632AF

P2860

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

http://www.wikidata.org/entity/Q37318124

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phenformin enhances the therapeutic benefit of BRAF

@nl

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

@en

type

label

Phenformin enhances the therapeutic benefit of BRAF

@nl

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

@en

prefLabel

Phenformin enhances the therapeutic benefit of BRAF

@nl

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

@en

P1433

Q37318124-C55C3F2E-39CC-4E0B-A142-2F343E503A9C

P1476

Q37318124-36D3E833-7835-418F-84E2-2AC4A93D4BF9

P2093

Q37318124-2B13FECD-2A0F-4CC3-BAC4-DD1C7A0681E6

Q37318124-36DFBCB8-C10B-4424-8686-400D75AB181C

Q37318124-4265EE02-0550-4CF6-8BD7-0F152757A128

Q37318124-5BA8891A-DA43-4F6C-9DEC-685BC245465E

Q37318124-5CE68D8F-6817-492F-8F47-C500E65E8B7B

Q37318124-B98F14AA-1726-4AEC-BFE0-1163B1B0239D

Q37318124-BA1079A5-43DF-461A-832F-43E6C7A591E1

Q37318124-BAD7A29B-18E0-4FE4-A4AB-7C3DB3F8243F

Q37318124-BB93F52E-23DE-4F28-ADCD-497A3AEDC0D3

P2860

Q37318124-03FADCAF-BBDD-4708-A631-8D132A0D80D9

Q37318124-0B6C6662-32F4-4713-B5FF-E870CBDA4973

Q37318124-1AB4D50D-97DD-4BD5-BD22-0ED0C4690ED7

Q37318124-1F147101-25B3-4018-B61E-D3F285878509

Q37318124-274A417C-3EC9-4C00-BFBD-168EBFEBFAF8

Q37318124-2B7BAD5F-FB19-437D-BA09-5FB372D12CC7

Q37318124-30CE3A7E-F168-4761-83BA-FB3BBD410089

Q37318124-326C5DEC-20F7-42E2-BBCF-1E5EC3588124

Q37318124-368FA404-F388-40A4-9AD4-09B41B6EB34C

Q37318124-36B876F5-3A7A-4FA8-9327-88AEEB813FB3

P304

Q37318124-255F02A8-DCD2-4588-AEEE-EA566016C74C

P31

Q37318124-F2CF350A-6FCE-499B-BE80-B492851DF7E1

P356

Q37318124-E1D5B7F4-C849-4599-B077-A5CC71088EA6

P407

Q37318124-8BEA7D17-73C8-4756-8F42-60E39907C17B

P433

Q37318124-6282C711-8CF3-45BC-B5B1-F396491BEAD3

P478

Q37318124-27170D7F-3643-4AEE-BE3F-F845C2A05CD1

P50

Q37318124-D932FE36-3CFF-42EE-B951-1F7CFAE07CB2

P577

Q37318124-7A1F6F9C-7625-401E-A53F-196A54154596

P5875

Q37318124-C866935E-A37C-4B8D-808F-4F6FEF07C7BA

P698

Q37318124-9206317D-754C-4959-B847-1D0305753CD6

P932

Q37318124-117E5AA5-3069-4D66-AB72-B36011E86D9C

P356

PNAS.1317577110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

@en

P2093

Bin Zheng

http://www.w3.org/2001/XMLSchema#string

Che-Hung Shen

http://www.w3.org/2001/XMLSchema#string

Christina Del Guzzo

http://www.w3.org/2001/XMLSchema#string

Jung Hyun Lee

http://www.w3.org/2001/XMLSchema#string

Koichi Ito

http://www.w3.org/2001/XMLSchema#string

Marcus W Bosenberg

http://www.w3.org/2001/XMLSchema#string

Martin McMahon

http://www.w3.org/2001/XMLSchema#string

Ping Yuan

http://www.w3.org/2001/XMLSchema#string

Rolando Perez-Lorenzo

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Investigating metformin for cancer prevention and treatment: the end of the beginning

Melanoma: from mutations to medicine

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Raf kinases in cancer-roles and therapeutic opportunities

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

Drug combination studies and their synergy quantification using the Chou-Talalay method

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

Resistance to BRAF inhibition in melanomas.

Metformin and other biguanides in oncology: advancing the research agenda.

P304

18226-18231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1317577110

http://www.w3.org/2001/XMLSchema#string

P407

P433

45

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Lewis C. Cantley

P577

2013-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258064619

http://www.w3.org/2001/XMLSchema#string

P698

24145418

http://www.w3.org/2001/XMLSchema#string

P932

3831456

http://www.w3.org/2001/XMLSchema#string